Ask AI

CCO Independent Conference Coverage of IDWeek and EACS 2025: The Latest Updates in HIV *

Review downloadable slidesets, on-demand webcasts, a podcast, and expert-written ClinicalThought commentaries on key data from IDWeek 2025 and European AIDS Conference 2025 (EACS 2025) for all the latest updates in HIV.

Share

Program Content

17 Capsule Summaries

Activities

EMBRACE: N6LS Safety and Tolerability
EMBRACE: Safety and Tolerability of VH3810109 (N6LS) in People With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 22, 2025

CLARITY
CLARITY: Comparison of Long-Acting Injectable Antiretrovirals in Healthy Adults Without HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 22, 2025

PURPOSE 2 Subanalysis
PURPOSE 2 Subanalysis: Annual Persistence on Twice-Yearly LEN vs Daily FTC/TDF for PrEP Among Cisgender Men and Gender-Diverse People
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 22, 2025

Weekly Oral ISL and LEN
Once-Weekly Oral ISL + LEN in People Living With Virologically Suppressed HIV: Wk 96 Results
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

ACTG A5391 DO IT Metabolic Analysis
ACTG A5391/DO-IT: Metabolic Parameters and Body Composition After Switch to DOR ± TDF vs Continuing INSTI + TAF/FTC 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

Weight Gain in P052 Study
P052 (MK-8591A-052) Phase III Trial of Switch From BIC/FTC/TAF to Doravirine/Islatravir: Impact on Weight and Body Composition at Wk 48
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

EMPOWER
EMPOWER: Treatment Satisfaction of People Living With Virologically Suppressed HIV on LA ART Who Switched to Daily Oral BIC/FTC/TAF
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

Lenacapavir Teropavimab Zinlirvimab
Phase II Study of Lenacapavir, Teropavimab, and Zinlirvimab in People Living With Virologically Suppressed HIV: Wk 52 Results
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 23, 2025

PREFER-LA
PREFER-LA: Switch to LA CAB + RPV in People Living With HIV and Previous Adherence Challenges
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2025

LEN PrEP in Substance Use
PURPOSE 2: Adherence to and Safety of Lenacapavir for PrEP Among People Who Use Substances
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2025

MORE At Home HIV Care
MORE Program: At-Home LA CAB + RPV Injections for People Living With HIV Experiencing Adherence Challenges
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2025

PURPOSE 2 LEN and GAHT
PURPOSE 2: Pharmacokinetic Effects of Lenacapavir on Gender-Affirming Hormone Therapy in Gender-Diverse People 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 27, 2025

PREFER LA
PREFER-LA: Real-world Efficacy of Switch to LA CAB + RPV in People Living With HIV and Adherence Challenges 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2025

LEN Real World Adherence
Real-world Lenacapavir Efficacy and Adherence: Long-term Follow-up From the OPERA Cohort
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2025

Zoster Vaccination in HIV
Impact of Zoster Infection and Vaccination on Cardiovascular Risk and Mortality in People Living With HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 28, 2025

MK-8591A-054
MK-8591A-054: Interim Analysis of Safety and Efficacy of Reduced-Dose DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2025

LEN in HTE HIV
Real-world Lenacapavir in Heavily Treatment–Experienced People Living With HIV: Virologic Outcomes, Pill Burden, and Number of Total and Active Agents
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.